Astrocytes are acutely sensitive to 1,3-dinitrobenzene (1,3-DNB) while adjacent neurons are relatively unaffected, consistent with other chemically-induced energy deprivation syndromes. Previous studies have investigated the role of astrocytes in protecting neurons from hypoxia and chemical injury via adenosine release. Adenosine is considered neuroprotective, but it is rapidly removed by extracellular deaminases such as adenosine deaminase (ADA). The present study tested the hypothesis that ADA is inhibited by 1,3-DNB as a substrate mimic, thereby preventing adenosine catabolism. ADA was inhibited by 1,3-DNB with an IC 50 of 284mM, Hill slope, n 5 4.8 ± 0.4. Native gel electrophoresis showed that 1,3-DNB did not denature ADA. Furthermore, adding Triton X-100 (0.01-0.05%, wt/vol), Nonidet P-40 (0.0015-0.0036%, wt/vol), or bovine serum albumin (0.05 mg/ml or changing [ADA] (0.2 and 2nM) did not substantially alter the 1,3-DNB IC 50 value. Likewise, dynamic light scattering showed no particle formation over a (1,3-DNB) range of 149-1043mM. Kinetics revealed mixed inhibition with 1,3-DNB binding to ADA (K I 5 520 ± 100mM, n 5 1 ± 0.6) and the ADA-adenosine complex (K IS 5 262 ± 7mM, n 5 6 ± 0.6, indicating positive cooperativity). In accord with the kinetics, docking predicted binding of 1,3-DNB to the active site and three peripheral sites. In addition, exposure of DI TNC-1 astrocytes to 10-500mM 1,3-DNB produced concentration-dependent increases in extracellular adenosine at 24 h. Overall, the results demonstrate that 1,3-DNB is a mixed inhibitor of ADA and may thus lead to increases in extracellular adenosine. The finding may provide insights to guide future work on chemically-induced energy deprivation.
Used as an industrial synthetic intermediate, 1,3-DNB has been shown to elicit profound histopathological changes in the male reproductive system, liver, and central nervous system (Blackburn et al., 1988; Bond et al., 1981; Philbert et al., 1987) . The clinical manifestations of neurotoxicity include nausea, vomiting, hearing loss, and cognitive deficits, depending on the dose and duration of exposure (Cody et al., 1981) . Histopathological evaluation of brains from exposed rats reveals focal bilateral edematous lesions in the vestibular and auditory pathways of the brainstem. Astrocytes are the primary targets of 1,3-DNB, and severe neuronal damage is absent during the acute phase of intoxication (Philbert et al., 1987) . Neuropathological changes are associated with regional increases in glucose consumption and lactic acid formation as well as decreased adenosine triphosphate (ATP) concentrations in affected areas of the brain (Brown and Miller, 1991; Romero et al., 1995) . Recently, our laboratory demonstrated that 1,3-DNB inhibits the pyruvate dehydrogenase complex in rat C6 glioma cells (Miller et al., 2011) . Nevertheless, the precise molecular mechanisms of 1,3-DNB-linked differential cellselective neurotoxicity have remained largely elusive.
ATP and its metabolites, e.g., adenosine diphosphate, adenosine monophosphate (AMP), and adenosine, are critical modulators of cellular sensitivity to a variety of endogenous and exogenous challenges (Burnstock, 2006; North and Verkhratsky, 2006; Ribeiro and Sebastiao, 2010) . In particular, adenosine binds to adenosine receptors and modulates adenylyl cyclase activity, leading to a variety of subsequent biological responses under both physiological and pathological conditions (Fredholm, 2007) . Briefly, binding of adenosine to the four types of adenosine receptors either inhibits (A 1 R and A 3 R) or stimulates (A 2A R and A 2B R) adenylyl cyclase activity, thereby modulating downstream events through adenosine signaling pathways. Experiments conducted in A 1 R-knockout mice indicate that adenosine is important mainly in pathophysiological conditions (Johansson et al., 2001) . For example, the binding of adenosine to adenosine A 1 receptors during hypoxia reduces the release of excitatory neurotransmitters. This inhibitory action has been demonstrated to contribute to neuroprotection mainly during hypoxia and seizures (Latini and Pedata, 2001) .
Adenosine homeostasis is maintained by its formation, metabolism, and transport pathways. The primary pathway for the formation of adenosine is via hydrolysis of intracellular and extracellular AMP. The enzymes that aid in the catalysis of these processes are 5#-nucleotidase and ecto-5#-nucleotidase, with rate constants (K M ) in the millimolar and micromolar range, respectively (Latini and Pedata, 2001) . It has been proposed that in neurons, production of adenosine proceeds primarily via the intracellular pathway, whereas in astrocytes, extracellular production is dominant (Parkinson et al., 2005) . Intracellular S-adenosylhomocysteine hydrolysis also contributes to formation of adenosine, but this source is not significant in the brain (Pak et al., 1994) . Most adenosine metabolism depends on two pathways: phosphorylation to AMP by adenosine kinase (AK, EC 2.7.1.20) or deamination to inosine by adenosine deaminase (ADA, EC 3.5.4.4). In human whole brain, the K M value of AK was reported to be 2lM, whereas the K M value of ADA was approximately 20lM (Phillips and Newsholme, 1979) . With a lower K M value, AK also exhibits substrate inhibition at a relative low level of adenosine (> 0.5lM). Adenosine influx and efflux is mediated by the equilibrative nucleoside transporters, which allow purine and pyrimidine nucleosides to traffic across the membrane in a concentration-driven mode (Latini and Pedata, 2001 ). The conversion of adenosine to inosine, which is meditated intracellularly and extracellularly by cytosolic and ecto-ADA, respectively, is crucial, as adenosine is the active neurotransmitter, whereas inosine is inactive. Thus, modification of ADA activity results in changes in adenosine levels, potentially leading to altered synaptic transmission. With the most obvious role reported to be degradation of endogenous adenosine, ecto-ADA also has been shown to be essential for the effectiveness of A 1 R and G protein interactions (Cristalli et al., 2001) .
Found ubiquitously in living organisms, ADA is a 41 kDa zinc metalloprotein with a wide distribution in most human tissues (Cristalli et al., 2001) . As a key enzyme in purine metabolism, the active site of ADA is highly conserved within the three mammalian species: murine, bovine, and human (Cristalli et al., 2001) . ADA exists as two isoforms. The first isoform, ADA1, is localized in the cytosol and cell surface of most tissues and thus is termed cytosolic ADA and ecto-ADA, respectively. On the other hand, the second isoform, ADA2, is produced by macrophages and found in blood plasma (Cristalli et al., 2001) . The present study focuses on the ADA1 isoform, which will be referred to simply as ADA in this paper.
Inhibitors of ADA have been categorized as ground-state or transition-state substrate analogs and as ground-state inhibitors that do not closely mimic substrates. Binding of substrate analogs triggers a conformational change from the open state to the closed state of the enzyme, whereas other inhibitors bind to the open conformation (Cristalli et al., 2001; Kinoshita et al., 2005 Kinoshita et al., , 2008 .
We hypothesized that 1,3-DNB would bind to the closed form of ADA as a substrate-mimic inhibitor due to the fact that the substrate-mimic adenine inhibits ADA (Alunni et al., 2008) , and the benzene ring of 1,3-DNB can be mapped onto the adenine component of adenosine, with its nitrogens superimposed on adenine's amino and N9 nitrogens as shown in Figure 1 . The similarity in the shape of 1,3-DNB and adenine can be quantified by the degree of overlap of molecular volumes, yielding a Tanimoto coefficient of 0.827, where a perfect match would be exactly 1.000 (Butina, 1999) . In addition, given that the nitro group of an inhibitor of carboxypeptidase A coordinates with the zinc atom of that metalloenzyme (Wang et al., 2008) , we postulated that a nitro group of 1,3-DNB could bind to the zinc atom in the active site of ADA.
The present study explored the mechanism of ADA inhibition by 1,3-DNB. In this paper, we report that 1,3-DNB inhibits ADA with an apparent IC 50 of 284lM. Furthermore, our kinetics studies found that the rate of inhibition depended upon substrate concentration, indicating that 1,3-DNB is a mixed inhibitor of ADA, in agreement with our modeling studies, which predict binding of 1,3-DNB to the active site as well as peripheral sites.
MATERIALS AND METHODS
Chemicals. Dimethyl sulfoxide (DMSO), 1,3-dinitrobenzene (1,3-DNB), adenosine, potassium phosphate monobasic (KH 2 PO 4 ), bovine serum albumin (BSA), bromophenol blue, Coomassie blue, and guanidine hydrochloride were obtained from Sigma (St Louis, MO). Potassium hydroxide (KOH), toluene, acetone, glycerol, Tris base, Tris-HCl, and glycine were obtained from Fisher Scientific (Pittsburgh, PA). Bovine intestinal ADA (EC 3.5.4.4.) was purchased from Calbiochem (San Diego, CA). Triton X-100, Precision Plus Protein Dual Color Standards, Immuno-Blot polyvinylidene fluoride (PVDF) membranes, 12% Ready Gel Tris-HCl Gel, and 4-15% Ready Gel Tris-HCl Gel were purchased from Bio-Rad Laboratory (Hercules, CA). Nonidet P-40 was from USB Corporation (now Affymetrix, Santa Clara, CA). Novex Sharp Standard, Dulbecco modified Eagle's medium (DMEM); penicillin, streptomycin, glutamate (PSG); Dulbecco's phosphate-buffered saline (D-PBS); and fetal bovine serum (FBS) were obtained from Invitrogen (Carlsbad, CA). Adenosine and inosine sensors were purchased from Sarissa Biosensor (Coventry, U.K.). BCA protein assay kits and Subcellular Protein Fractionation kits were obtained from Thermo Scientific (Rockford, IL). Rabbit anti-rat ADA and rabbit anti-rat A 1 R were purchased from Abcam (Cambridge, MA).
ADA assay. ADA activity was assayed following the method described by Kaplan (1955) , using a Cary 100 Bio spectrophotometer (Varian, Santa Clara, CA). The purchased enzyme (ADA) was > 95% pure as determined by SDS gel electrophoresis. The assay was performed at a final volume of 1.00 ml containing 100mM potassium phosphate buffer (pH 7.5 at room temperature), 0.50nM ADA, a fixed percentage of DMSO (5%, vol/vol) , and various concentrations of adenosine (ranging from 4 to 200lM) and 1,3-DNB (ranging from 140lM to 2mM). Under these conditions, the observed absorbance at 265 nm decreased due to the conversion of adenosine to inosine with a net negative change of 9800/M/cm. The ADA activity was measured from the initial linear decrease in absorbance at 25°C, and activities were calculated relative to contemporaneous DMSO-containing controls. The absorbance from the first 7 min was recorded, and the absorbance from the first minute, comprising 7-9 data points, was used to calculate the initial velocity.
DI TNC-1 cell culture. Immortalized astrocytes DI TNC-1 were obtained from American Type Culture Collection. DI TNC-1 cells were kept in an incubator at constant temperature (37°C) with 5% CO 2 /95% air (vol/vol) 510 supply. DMEM supplemented with 10% (wt/vol) FBS and 1.0% PSG (vol/vol) was used for cell culture. Following 48 h of initial subculture plating, cells were rinsed with 5 ml D-PBS and treated by 1 ml 0.25% (wt/vol) trypsin. DI TNC-1 were exposed to 10 ml serum-free media containing either 0.5% DMSO, 10, 100, or 500lM 1,3-DNB. One hour after the exposure, serum (1.00 ml) was added into each plate containing conditioned media and then DI TNC-1 cells were continued incubating for 23 h. Four independent experiments were conducted for each exposure with DI TNC-1 passage 4-10.
Measurement of adenosine and inosine from DI TNC-1 conditioned media. Adenosine, inosine, and null sensors were linked to a Multi-Channel Potentiostat (Pinnacle Technology, Lawrence, KS). Standard solutions of adenosine and inosine (1-50lM) were used for calibration. Toluene (1.0 ml) was added to 11 ml of collected conditioned media to extract 1,3-DNB.
Extraction was performed twice for each DMSO or 1,3-DNB exposure. Adenosine and Inosine levels were measured and calibrated to protein concentration obtained by BCA protein assay.
Aggregation-based inhibition. All reactions were performed at 25°C using 100mM potassium phosphate buffer (pH 7.50 at room temperature), 0.50nM ADA, and 5% (vol/vol) DMSO. Adenosine concentration was held at 50lM, whereas 1,3-DNB concentrations were varied from 275 to 1000lM. The IC 50 was determined under four conditions: (1) addition of Triton X-100 at 0.01, 0.02, and 0.05% (wt/vol); (2) addition of Nonidet P-40 (NP-40) at 0.0015, 0.0024, and 0.003%; (3) addition of BSA (0.1 mg/ml); and (4) increasing the concentration of ADA to 1.49nM. The ADA activity was measured from the initial linear decrease in absorbance at 25°C. All reactions were initiated by the addition of adenosine into the cuvette.
FIG. 1.
Structural and sequence alignments of 1,3-DNB and ADA. (A)-(C) Models of (A) 1,3-DNB, (B) Adenine ring of adenosine, and (C) 1,3-DNB superimposed on the adenine ring of adenosine. Small molecule alignment was carried out in YASARA and depicted using PyMOL. For quantification, molecular alignment was done with vROCS 3.1.2, yielding a shape Tanimoto coefficient of 0.827 between 1,3-DNB and the adenine ring of adenosine (a perfect shape match would yield a Tanimoto coefficient of exactly 1.000). Molecules are shown as capped sticks within semitransparent space-filling spheres. Atom colors: carbon ¼ green (1,3-DNB) or cyan (adenine); nitrogen ¼ dark blue; oxygen ¼ red; and hydrogen ¼ white. (D) Sequence alignments of the human, murine, and bovine forms of ADA. Conserved residues are shaded in either black (identical residues) and gray (similar residues); overall pairwise sequence identity is 85.8% across the three species.
ADENOSINE DEAMINASE INHIBITION BY 1,3-DNB Time dependence. Five nanomolar of bovine ADA in 0.1M potassium phosphate buffer (pH 7.5) was treated with 5.5mM 1,3-DNB or 5% (vol/vol) DMSO. The protein and ligand were mixed gently in a conical tube and incubated at 25°C. At the specified time points (0, 15, 30, 45 , and 60 min), the protein-ligand solution was added to prewarmed cuvettes at 25°C containing 10 ll adenosine at 5mM. ADA activity was measured at 25°C for 7 min, and the absorbance from the first minute, comprising 7-9 data points, was used to calculate the initial velocity.
Native gel electrophoresis. ADA (3.6 lg) was loaded into each lane of a 12% Tris-HCl polyacrylamide gel following preincubation for 30 min on ice with either DMSO or 1,3-DNB (0.35-1mM). Positive controls for denatured proteins were prepared by either heating ADA at 95°C for 5 min in a dry bath incubator or via denaturation using 3M guanidine hydrochloride for 30 min on ice, before loading onto the gel. Sample buffer contained 0.125M Tris-HCl at pH 6.8, 20% (vol/vol) glycerol and 1% (wt/vol) bromophenol blue in Milli-Q water. The gel was run as detailed earlier (Coligan, 1996) . Briefly, the gel was prerun for 60 min on ice with voltage held constant at 200 V. After samples were loaded, the gel was continuously run on ice for 3 h at constant current of 0.04 A in a Tris-glycine buffer. The gel was then stained with Coomassie blue and imaged using a FOTO/Analyst Investigator (Fotodyne, Hartland, WI).
Measurement of particle size using dynamic light scattering. Particle size measurements were undertaken at 10°C, 25°C, and 37°C using a DelsaNano C Particle Analyzer (Beckman Coulter, Brea, CA) with 1,3-DNB ranging from 149 to 1043lM in 0.1 potassium phosphate (pH 7.5 at room temperature) with a DMSO concentration of 14.9% (vol/vol). In a separate experiment, the DMSO concentration was varied from 0.1 to 20% (vol/vol), whereas the concentration of 1,3-DNB was maintained at 1mM.
Kinetics studies of 1,3-DNB inhibition of ADA. The inhibition of ADA activity was first measured at a fixed concentration of adenosine (50lM) and varying concentrations of 1,3-DNB (0-2mM). A value for an apparent IC 50 was calculated by fitting Equation 1 to the data.
where X ¼ (1,3-DNB) and n ¼ Hill slope. The Hill slope allows fitting for cooperative inhibition. To further analyze inhibition, ADA activity was measured with varying adenosine concentrations (4-200lM) at several fixed 1,3-DNB concentrations (200-350lM) , from the initial linear decrease in absorbance at 25°C. The inhibition mechanism was analyzed using the global fitting function of GraphPad Prism 5.03. Four possible inhibition mechanisms, including ''competitive, uncompetitive, noncompetitive and mixed inhibition,'' were fitted to the dependence of the ADA activity on adenosine and 1,3-DNB concentrations. The global fitting function analyzes multiple data sets simultaneously to generate one (global) best-fit value of parameters for all of the data sets. Global fitting was performed using equations derived from Figure 2 showing mixed inhibition.
Equation 2 describes the mixed inhibition mechanism, whereas Equation 3 describes the noncompetitive mechanism, whereby 1,3-DNB binds only to the ES complex.
Molecular modeling. To gain insight into the structural basis of the interactions of 1,3-DNB with ADA, in silico docking studies were performed using the structures of murine (PDB ID 3MVI), bovine (PDB ID LKRM), and human ADA (PDB ID 3IAR). The human crystal structure was solved with Ni 2þ in the active site, which was replaced by Zn 2þ using YASARA Structure 11.3.22 (YASARA Biosciences, Vienna, Austria) (Krieger et al., 2004) , so that the zinc metalloprotein was used for docking studies of all three species of ADA. Although the protein is monomeric, in crystal structures where two protein molecules were visible in the asymmetric unit, the A chain was selected for docking studies. The crystal structure of bovine ADA was found to contain seven cis-peptide bonds in its peptide backbone. Cis-peptide bonds are usually not favored except at proline residues (Pal and Chakrabarti, 1999) , and as such, all cispeptide binds were corrected in YASARA. However, analysis of the human ADA structure revealed a cis-peptide bond between E113 and P114 (corresponding to E110 and P11 in bovine ADA). As a result, a cis-bond was added in silico to the peptide backbone of the energy-minimized structure of bovine ADA between E110 and P111. The resulting structure was refined via local annealing and subjected to a second round of energy minimization as described below. The two cis-peptide bonds in the murine ADA structure were confirmed via examination of the electron density map and were left uncorrected, in contrast to the seven cispeptide bonds in the bovine ADA structure that could not be confirmed. Moreover, using Clustal Omega 1.0.3, alignments of the primary amino acid sequences of murine, human, and bovine ADA revealed these proteins to share 85.8% pairwise sequence identity (Fig. 1D) . Furthermore, all ADA structures used in the present study represent the closed form of the enzyme, which is expected to be optimal for binding substrate analogs (Kinoshita et al., 2005) .
The structures of 1,3-DNB and the adenine ring of adenosine were generated in ChemBioDraw Ultra 12.02 (CambridgeSoft, Cambridge, MA) and optimized in MarvinSketch 5.4.1.1 (ChemAxon, http://www.chemaxon.com). The resulting structures were further refined via the energy minimization protocol in YASARA using the AMBER03 force field (Duan et al., 2003) prior to their use in docking or molecular alignments. The structure of adenosine for docking was obtained from the 2#-deoxyadenosine ligand in the crystal structure of human ADA (PDB ID 3iar); the 2#-hydroxyl group was inserted using YASARA. Molecular alignments of 1,3-DNB and the adenine ring of adenosine were carried out in YASARA and vROCS, version 3.1.2 (OEChem, version 1.7.2; OpenEye Scientific Software, Inc., Santa Fe, NM, www.eyesopen.com, 2011) . Prior to their use in docking, the ADA structures were ''cleaned'' and energy-minimized using the corresponding protocols in YASARA and the AMBER03 force field. Twenty-five sequential global docking runs of the ligands (1,3-DNB or adenosine) onto the prepared receptors (murine, bovine, or human ADA structures) were undertaken within a cubic simulation cell (a ¼ b ¼ c ¼ 46 Å ) centered on the protein molecule. All docking runs were performed using the modified version of AutoDock 4.2.3 (http://autodock.scripps.edu) (Morris FIG. 2 . Model describing inhibition of ADA (E) catalyzed deamination of adenosine (S) to form inosine (P) by 1,3-dinitrobenzene (I, 1,3-DNB). The mixed inhibition observed for DNB indicates that the inhibitor both competes with adenosine for binding to E, as described by the inhibition constant, K I , and binds to the ES complex, as described by the inhibition constant K IS . 512 et al., 1998) distributed with YASARA. The AMBER03 force field and the Lamarckian Genetic Algorithm were used for docking. All atoms in the receptors were held rigid during docking, but flexibility was allowed in the amino and hydroxyl groups of adenosine and the nitro groups of 1,3-DNB. The final docked ligand poses were analyzed in YASARA and PyMOL version 1.4 (Schrödinger, Cambridge, MA) using a root mean square deviation cutoff of 5.0 Å to define a cluster of ligand conformations.
Cell fractionation. Immortalized astrocytes (DI TNC-1) were harvested, and subcellular protein from cytoplasmic extract and membrane extract were prepared using instructions provided by the supplier (Thermo Scientific). Briefly, 1 3 10 6 trypsinized DI TNC-1 cells were collected in tubes and pelleted via centrifugation at 500 3 g for 5 min. The cells were rinsed with ice-cold PBS and pelleted by centrifugation at 500 3 g for 3 min. After the supernatant was discarded, 100 ll ice-cold Cytoplasmic Extraction Buffer (CEB) was added to the pellet. Next, the cells were incubated with CEB for 10 min with rocking at 4°C. Following centrifugation at 500 3 g for 5 min, the supernatant was collected as cytoplasmic extract. 100 ll ice-cold Membrane Extraction Buffer (MEB) was added to the pellets. The pellets were suspended in MEB and incubated for 10 min with gentle rocking at 4°C following which the samples were centrifuged at 3000 3 g for 5 min, and the supernatant was collected as membrane extract. Protein samples for ADA detection were prepared as described in the previous section (Cell Fractionation). Equal amounts of protein (30 lg) were loaded into each well. The gels were run for 90 min in Tris-glycine buffer with 0.1% SDS (vol/vol) at a constant voltage of 200 V. The separated protein mixtures were then transferred onto PVDF membranes (BioRad) at a constant voltage of 120 V for 40 min. The membranes were blocked in 0.5% (wt/vol) nonfat dry milk using SNAP ID (Millipore, Billerica, MA) and incubated with primary antibodies against A 1 R (1:1000, Abcam) or ADA (1:2500, Abcam). The bands were visualized via phosphorimaging using a Fujifilm FLA-5000 (Tokyo, Japan) following development using the ECF Western Blotting Reagent Pack (GE Healthcare, Piscataway, NJ).
Statistical analysis. Statistical differences between groups were determined by one-way ANOVA followed by multiple comparisons undertaken using a Tukey post hoc test. All statistical analyses were undertaken in GraphPad Prism 5.03 (GraphPad Software Inc., La Jolla, CA). A p value cutoff of 0.05 was used to determine statistical significance.
RESULTS
1,3-DNB Inhibits ADA Activity Figure 3 shows that the activity of ADA decreased upon addition of 1,3-DNB, indicating that this compound inhibits ADA. The inhibitory activity shows a sharp dependence on 1,3-DNB concentration, suggesting a cooperative inhibition mechanism. Therefore, to obtain a value for the IC 50 , a sigmoid curve model that allows for cooperative inhibition (Equation 1) was fit to the data (R 2 ¼ 0.953). This analysis gave an apparent IC 50 value for 1,3-DNB of 284lM, with a Hill slope (n) of 4.80 ± 0.44. This corresponds to an apparent IC 50 (95% CI) of 273 (263-283)lM.
Effect of 1,3-DNB on the Extracellular Adenosine and Inosine Level in Conditioned Media
Cells that were unexposed to solvent or 1,3-DNB had extracellular adenosine levels below the limit of detection (50nM) (data not shown). In the vehicle control group (DMSO 0.50%, vol/vol), the adenosine level was also below 50nM during the 24-h exposure period. The highest 1,3-DNB concentration (500lM) produced a significant elevation in the concentration of inosine þ hypoxanthine, whereas the two highest 1,3-DNB concentrations (100 and 500lM) produced elevated adenosine levels compared with the control group (p < 0.05) in the 24-h exposure (Fig. 4) .
Aggregation-Based Inhibition Test
To examine whether 1,3-DNB inhibition is caused by aggregation, four common characteristics of aggregators were investigated. These are as follows: (1) inhibition is markedly sensitive to nonionic detergents, e.g., decreasing in potency by   FIG. 3. 1,3 -DNB inhibits the activity of ADA. The activity of ADA was measured at 50lM adenosine and varied 1,3-DNB concentrations (35, 70, 140, 175, 200, 250, 275, 300, 350, 400, 700, 1000, and 2000lM) . Symbols represent mean ± SEM (n ! 3) from different experiments. The solid line is the fit of Equation 1 to the data. 1,3-DNB was extracted with toluene from the conditioned media before measurement. DMSO, as the vehicle control, was tested at 0.5%, 1,3-DNB concentrations were 10, 100 and 500lM. The exposure time was 24 h for all groups. Adenosine level was below detection limit for the DMSO-treated group and therefore the negative values from readings were substituted with zero. Four independent experiment results were collected and normalized against protein concentrations of each sample. Bars represent mean ± SEM. ADENOSINE DEAMINASE INHIBITION BY 1,3-DNB a factor of two or more, (2) inhibition occurs by nonspecific binding to protein, (3) inhibition is sensitive to the enzyme concentration, and (4) the inhibitor forms particles that are detectable by dynamic light scattering (DLS) in the absence of the enzyme (Seidler et al., 2003) . First, two different nonionic detergents Triton X-100 (Fig. 5) and Nonidet P-40 (data not shown) were used to test whether 1,3-DNB inhibition of ADA is highly sensitive to detergents. There was no significant change in the IC 50 value produced by Nonidet P-40 and although the change (À6%) in the IC 50 from Triton X-100 was only À26%, it is in the wrong direction (increased rather than decreased potency) and smaller in magnitude than the factor of two or more deemed necessary for an aggregating inhibitor. Next, the specificity of inhibition was tested via the addition of BSA at a final concentration of 0.05 mg/ml (data not shown). Under this condition, the IC 50 , 284lM, was not significantly different from the value in the absence of BSA, 301lM (p > 0.1). Then, we demonstrated that the IC 50 value of 1,3-DNB was unaffected (p > 0.50) by increasing the concentration of ADA from 0.2 to 2.0nM (data not shown), with measured IC 50 (micromolar) values of 275 and 279lM, respectively. Finally, no particles were detectable by DLS over a 1,3-DNB concentration range from 149 to 1043lM (data not shown). Taken together, these results demonstrate that 1,3-DNB does not exhibit the common properties of an aggregation-based inhibitor.
Time Dependence
To determine whether the inhibition of ADA by 1,3-DNB is time dependent, ADA was preincubated with DMSO or 1,3-DNB, and the activity as a function of preincubation time was measured. Relative ADA activity was obtained by comparing the ADA activity in DMSO or 1,3-DNB preincubated ADA with buffer preincubated ADA. A constant decrease in enzyme activity corresponding to 20% in the presence of DMSO and 50% in the presence of DMSO þ 1,3-DNB was observed over the 60-min time-course groups (Fig. 6 ). This finding suggests that the inhibition of ADA by 1,3-DNB is not dependent upon the time of incubation.
Denaturation Experiment
To further examine the inhibitory mechanism of 1,3-DNB, native gel electrophoresis was employed to examine the possibility that this compound decreases ADA activity by denaturing the protein. In the gel, the band for ADA in the lanes preincubated with DMSO and 1,3-DNB (lanes 2-4) ran at the same position as native ADA (lane 1) (Fig. 7) . The position of denatured ADA was significantly altered, as observed for the lanes loaded with ADA denatured with either heat (lane 6) or guanidine hydrochloride (lane 7). These data demonstrate that incubation of ADA with 1,3-DNB does not lead to irreversible denaturation. Although it might seem theoretically possible to extend these results using fluorescence spectroscopy and circular dichroism, it was not possible to carry out these FIG. 5 . Evaluation of 1,3-DNB as an aggregation-based inhibitor. Triton X-100 was mixed with potassium phosphate buffer (100mM, pH 7.5) containing adenosine (50lM) and 1,3-DNB (35, 70, 140, 175, 200, 250, 275, 300, 350, 400, 700, 1000, and 2000lM) to final concentrations of 0.01, 0.02, and 0.05% (wt/ vol), then ADA (0.5nM) was added to initiate the reaction. Symbols represent mean ± SEM from at least three independent experiments for each point. 
Kinetics and Curve Fitting
The values determined for the steady-state kinetic parameters of ADA-catalyzed deamination of adenosine assayed at pH 7.5 and 25°C were k cat ¼ 23100 ± 960/min and K M ¼ 43 ± 3lM (Table 1) . Addition of 1,3-DNB led to decreased values for k cat , k cat /K M , and K M , indicating either mixed or noncompetitive inhibition (Table 1) . Mixed inhibition was chosen over noncompetitive because of its somewhat higher R 2 value and lower error in global fitting (Table 2 ). This agrees with the double reciprocal Lineweaver-Burk plot of ADA activity under different concentrations of 1,3-DNB, which exhibited changes in all three kinetic parameters, consistent with mixed inhibition (Fig. 8D) . Therefore, these data reveal that 1,3-DNB inhibits ADA using the mixed mechanism shown in Figure 2 with inhibition constants of K I ¼ 520 ± 100lM and K IS ¼ 262 ± 7lM.
ADA Has Multiple Potential 1,3-DNB Binding Sites: The Active Site and Peripheral Sites
Analysis of the docking results revealed the presence of four distinct clusters of 1,3-DNB poses on murine ADA (Fig. 9A) with estimated free energies of binding DG b ranging from À6.31 to À6.99 kcal/mol and corresponding estimated binding constants (K i ) ranging from 7.5 to 25.6lM. The cluster with the most favorable DG b (À6.99 kcal/mol) was centered in the active site of murine ADA with the active site zinc located 2.9 Å from the O2 atom of 1,3-DNB (Fig. 9B) , and the ND1 atom of His17 positioned 3.1 Å from the O4 atom of 1,3-DNB. The three additional energetically favorable clusters of 1,3-DNB poses were identified as centered on Arg156, Try240, and Val96, with predicted binding energies of À6.56, À6.47, and À6.31 kcal/mol, respectively. The murine ADA residues that contact 1,3-DNB are detailed in Table 3 . Similar results were obtained in docking experiments with 1,3-DNB against the bovine (PDB ID 1KRM) and human (PDB ID 3IAR) protein, with energetically favorable ligand poses evident in the active site, together with a putative peripheral binding site centered on Tyr240 (Table 3) . Docking 1,3-DNB onto bovine ADA revealed the most energetically favored site (DG b ¼ À7.68 kcal/mol) to be extraneous to the active site (DG b for 1,3-DNB docked into the active site ¼ À6.76 kcal/mol). However, this apparent anomaly could be an artifact due to the extensive predocking manipulations that were undertaken to clean and refine the bovine ADA structure, given its relatively low resolution (2.40 Å compared with 1.60 Å for murine ADA and 1.52 Å for human ADA) and its multiple cis-peptide bonds.
Similar results were obtained with docking adenosine into ADA, wherein the highest-scoring clusters were within the active site (DG b ¼ À9.19, À8.53, and À8.25 kcal/mol for human, murine, and bovine ADA, respectively). Among peripheral binding sites, one held in common among the three species of ADA was defined by Tyr240 (DG b ¼ À6.12, À5.83, and À6.01 kcal/mol for human, murine, and bovine ADA, respectively). The binding constants, K i , derived from these binding energies were in the range 0.19-0.89lM for the active site and 33-53lM for the Tyr240 peripheral site.
A 1 R and ADA Both Exist on DI TNC-1 Cells
As seen in Figure 10 , Western blotting analysis shows the presence of A 1 R and ADA in both cytoplasmic and membrane extracts in all groups of DI TNC-1 cells (nontreated, 0.5% DMSO (vol/vol) and 500lM 1,3-DNB for 24 h).
DISCUSSION
In this paper, we present evidence for a mixed mode of inhibition of ADA by 1,3-DNB. Following confirmation of the 
Goodness of Fit (Figs. 3 and 4) , the chemical basis of the mechanism of inhibition was further investigated. The Hill slope (n; steepness of the log IC 50 curve) of 1,3-DNB inhibition on ADA was approximately 5, suggesting possible aggregation, denaturation, or cooperative inhibition of ADA by 1,3-DNB (Prinz, 2009) . After the possibilities of aggregation (Fig. 5) and denaturation (Fig. 7) were eliminated, the kinetics of 1,3-DNB inhibition were examined. Substrate inhibition was also observed in steady-state turnover catalyzed by ADA when the adenosine concentration exceeded 150lM (data not shown). For our analysis, activity measurements were determined at adenosine concentrations in the range 4-75lM, where substrate inhibition was minimal. Then the steady-state kinetics parameters were determined by fitting the MichaelisMenten equation to the data. As summarized in Table 1 , addition of 1,3-DNB led to a decrease in the values of k cat , k cat / K M , and K M . The substantial decrease in the value of k cat indicates that 1,3-DNB inhibits ADA by binding to the ES complex, consistent with either mixed (binds to E and ES, Figure 2 ) or noncompetitive (binds to ES complex) inhibition. The decrease in the values of k cat /K M and K M are also consistent with a mixed inhibition mechanism. In addition, fitting k cat and k cat /K M values to Equation 4 revealed that 1,3-DNB binds to the ES complex, but not E, with positive cooperativity (Figs. 8A and B , n ¼ 5 ± 2 for k cat , whereas n ¼ 1 ± 0.6 for k cat /K M ). This cooperativity is consistent with the high Hill slope observed in IC 50 experiments. (Table  1) to Equation 4; (C) Best global fit for the kinetics of ADA in the presence of varying concentrations of 1,3-DNB and adenosine concentrations (4-75lM). Equation 2 derived for cooperative mixed inhibition (Fig. 2) is fitted to the data; (D) Lineweaver-Burk plot for the dependence of ADA activity on 1,3-DNB and adenosine concentrations. Symbols represent means ± SEM of at least four independent experiments at each concentration for all panels. 516
In the present study, the potential inhibitory effect of 1,3-DNB was examined at two levels of complexity: in a cell culture system and in a cell-free environment. Two higher 1,3-DNB concentrations (100 and 500lM) used in the former system were very close to the kinetic parameters calculated from the latter (IC 50 ¼ 283lM, K I ¼ 520lM, and K IS ¼ 262lM). Thus, it is reasonable to infer that the elevated adenosine level seen in the cell culture experiment was due at least in part to ADA inhibition. However, the IC 50 value obtained through the biochemical experiment should not be assumed to be the concentration that inhibited half of the ADA in the conditioned media, as in the more complex cellular system, 1,3-DNB can be metabolized, and ADA can turnover (Fig. 11) . Metabolically, active DI TNC-1 cells should be able to synthesize more ADA to replenish inhibited enzyme, given the fact that the viability of DI TNC-1 cells did not decrease significantly even with the highest 1,3-DNB concentration. In addition, ADA activity could be modified by more than one mechanism. For example, after metabolic activation, 1,3-DNB could covalently bind to proteins or cause protein carbonylation (Reeve and Miller, 2002; Steiner and Philbert, 2011) . Because brain tissue has the capacity to metabolize 1,3-DNB to its major metabolite, 1,3-nitroaniline, in 2 h (Hu et al., 1997) , it is possible that ADA could be inhibited in multiple ways by 1,3-DNB and its metabolites during the 24 h exposure, but this theory needs to be further validated.
The mechanism by which 1,3-DNB could increase extracellular adenosine concentrations has been summarized in Figure  11 . From cell and animal experiments, it is known that 1,3-DNB exposure causes a rapid disruption of mitochondrial function by inhibiting mitochondrial complex II in rat Table 3 .
ADENOSINE DEAMINASE INHIBITION BY 1,3-DNB brainstem and cortical astrocytes (Phelka et al., 2003) . This disruption of mitochondrial bioenergetics would likely result in reduced ATP production. A 44% decrease in cellular ATP level was observed in the susceptible neuroblastoma cell line SY5Y (Tjalkens et al., 2000) . The formation of the mitochondrial permeability transition pore (mtPTP) disrupts mitochondrial integrity and leads to rapid hydrolysis of ATP to adenosine via the reverse action of F 1 F 0 ATPase (Williams et al., 2005) . Because of ATP hydrolysis, which could happen both intraand extracellularly, metabolites such as adenosine and inosine are expected to increase. This theory is consistent with our observation of elevated extracellular adenosine level in the 1,3-DNB-treated groups. From the biochemical experiment in this study, we have also learned that 1,3-DNB could inhibit ADA within seconds, and this inhibition would be expected to further increase adenosine levels.
Once the adenosine concentration is elevated due to these primary events (labeled with I in Fig. 11) , it would in turn cause substrate inhibition of AK, the enzyme that phosphorylates adenosine to AMP. This mechanism would further increase the adenosine level as a secondary effect of 1,3-DNB toxicity (labeled with II in Fig. 11) .
In 1,3-DNB toxicity, astrocytes appear to be the primary target followed by secondary neuronal damage (Philbert et al., 1987) . As a universal neuromodulator with known neuroprotective effects (Stone et al., 2009) , adenosine is hypothesized to be a key player in 1,3-DNB neurotoxicity by binding to adenosine one receptors (A 1 R). A 1 R has been identified as 518 one of the two anchoring proteins for ecto-ADA in a variety of tissues, including brain (Cristalli et al., 2001) . One study, conducted using human brain tissue, suggested that ecto-ADA has dual functions, both reducing the extracellular adenosine concentration and binding to A 1 R as an allosteric effector to increase receptor functionality (Gracia et al., 2008) . As a mixed inhibitor of ADA, 1,3-DNB could influence the A 1 R signaling pathway by interfering with the dual functions of ADA. By inhibiting ADA, the local adenosine concentration around neurons would be elevated, allowing more adenosine molecules to bind to A 1 R, leading to decreased rates of firing (Fredholm, 2007; Fredholm et al., 2005) , and presumably, reduced ATP consumption and improved neuronal survival rate.
In our study, the DI TNC-1 cells were exposed for 24 h to three concentrations of 1,3-DNB (10, 100, and 500lM), which were within the range of 1,3-DNB concentrations that have been used previously on both DI TNC-1 cells and primary astrocytes to test viability. Although compared with the control group, the mitochondrial reductase activity of 500lM 1,3-DNB-treated DI TNC-1 cells exhibited an apparent decrease of 30% at the end of 24 h exposure. Statistical analysis showed that this reduction was not significant (p > 0.05) (Steiner and Philbert, 2011) . The other study done on primary astrocytes presented an unchanged lactate dehydrogenase release compared with the control group (p > 0.05) (Romero et al., 1995) . Thus, DI TNC-1 cell viability would not be expected to vary significantly in our experiment.
Besides cellular-level research, 1,3-DNB toxicity has also been studied extensively on animals. One of the commonly used dosages on rats ip is 10 mg/kg/day in DMSO. Table 4 compiles several studies that use this same dosage but on rats with different genders and body weights. If we calculate the blood volume of the rats using the equation below (Lee and Blaufox, 1985) : then by c ¼ n/BV, we can estimate the blood concentration of 1,3-DNB upon treatment as approximately 900mM. Because the brain and other tissues have the ability to metabolize 1,3-DNB (Hu et al., 1997; Reeve and Miller, 2002) , the real-time 1,3-DNB concentration would be expected to decrease gradually from this estimate. Thus, the highest 1,3-DNB concentration (500lM) used in our study falls below the blood concentrations estimated from in vivo studies.
Previously reported values for the K M of adenosine as a substrate for ADA encompass a span of 13-53lM, depending upon temperature, pH, and ionic composition of the buffer (Xu and Venton, 2010) ; thus, our value of 43 ± 3lM determined at pH 7.5 and 25°C falls within this range. The k cat is expected to increase with increasing temperature with a Q10 between 2 and 4 (Wolfenden and Snider, 2001) . At pH 7.5 and 20°C, the k cat was reported to be 11,940/min (Kurz et al., 1992) ; our value of 23,100/min determined at pH 7.5 and 25°C yields a Q10 of 3.7 and therefore lies within the scope of expected values.
The extracellular adenosine level in the DI TNC-1 cells upon exposure to 1,3-DNB at 500lM was about 0.33 pmol/lg protein, which is comparable to 1.5 pmol/mg wet tissue, the reported adenosine levels in hypoxic conditions (Takahashi FIG. 11 . The proposed mechanism of increased adenosine level in 1,3-DNB toxicity. The primary effects of 1,3-DNB include mitochondrial malfunction, which results in increased ATP hydrolysis and leakage, and inhibition of ADA (Roman number I, solid line). These events lead to increased extracellular adenosine level in a 1,3-DNB concentration-dependent manner. The elevated adenosine level, in return, inhibits the activity of AK (Roman number II, solid line). This is a secondary event that happens only when the adenosine level is above 0.5lM. Whether the inhibition of ADA would affect the binding of adenosine to A 1 R has remained untested in this study, and thus is marked by a dashed line with a question mark. Cells also have the ability to metabolize 1,3-DNB and synthesize new ADA, adding more complexity to the system. Although not tested in this study, it has been reported that by binding to A 1 R, adenosine has been observed to have neuroprotective effects. , 2010) . Given that 1,3-DNB induces methemoglobinemia (Cody et al., 1981) , resulting in reduced capacity of oxygen transport, it is expected that hypoxia-like pathology would be seen in 1,3-DNB neurotoxicity. In another study using enzymebased sensors, adenosine concentration was reported to be about 20lM from rat hippocampal slices after hypoxia (Frenguelli et al., 2003) , which is similar in magnitude to our data (about 30lM) in conditioned media before normalization against total protein. Taken together, these results indicate that our investigation provides an accurate and convenient way to quantify extracellular adenosine levels in studies of 1,3-DNB neurotoxicity and other similar pathological conditions in vitro.
Our in silico findings with the murine and human forms of ADA show the most energetically favorable 1,3-DNB conformations to be within the active site of the enzyme (Fig. 9 and Table 3 ). Binding to the active site would be expected to occur when extracellular adenosine concentrations are low (k cat /K M condition) because the affinity of adenosine to ADA is much higher than that of 1,3-DNB, both as predicted by our docking results and as determined experimentally (Frick et al., 1986) . This low concentration of adenosine suggests low occupancy of the ADA catalytic center and very likely binding of 1,3-DNB to the active site. Additionally, the high concentration of 1,3-DNB used in this study (500lM) leads to the possibility that several peripheral sites were occupied with predicted lowest energy conformations ranging from À6.02 to À6.84 kcal/mol for all three species of ADA (Table  3 ). In particular, the site defined by Try240 presents a putative allosteric-binding site and a target for future investigations into the interaction between ADA and its inhibitors.
Whereas theoretical DG b and K I values can often be used to rank the relative potencies of ligands for a binding site or, in this case, to rank the relative favorability of binding sites for a given ligand, it is considered problematic to use these values to predict absolute values of experimental binding constants (Ferrara et al., 2004) . For example, our experimental results demonstrate that the absolute inhibitory potency of 1,3-DNB for ADA is up to 70 times less than that predicted by docking. Nevertheless, the relative similarities in DG b values among the identified ligand clusters indicate likely binding to the active site accompanied by probable interactions with potential allosteric sites defined by Arg156, Try240, and Val96. Thus, our docking studies are in accord with our kinetics results, together predicting additional allosteric sites of interaction between 1,3-DNB and ADA, thereby presenting avenues for future research.
Taken together, this work presents biochemical evidence that 1,3-DNB inhibits the activity of ADA, which could contribute to the observed elevated extracellular adenosine level of approximately 0.33 pmol/lg protein. However, given that our studies have been conducted in vitro and in silico, further investigations into the in vivo interactions between 1,3-DNB and ADA are needed to gain a more complete understanding of this interaction in a physiological context. 
